Forsta AP Fonden Lowers Stock Holdings in Abbott Laboratories $ABT

Forsta AP Fonden trimmed its stake in Abbott Laboratories (NYSE:ABT) by 1.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 557,100 shares of the healthcare product maker’s stock after selling 6,100 shares during the period. Forsta AP Fonden’s holdings in Abbott Laboratories were worth $69,799,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Patrick Mauro Investment Advisor INC. raised its holdings in shares of Abbott Laboratories by 4.0% in the 4th quarter. Patrick Mauro Investment Advisor INC. now owns 5,411 shares of the healthcare product maker’s stock valued at $678,000 after purchasing an additional 210 shares in the last quarter. Norges Bank bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $2,938,892,000. Madison Wealth Partners Inc bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $259,000. Eurizon SLJ Capital Ltd bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $521,000. Finally, Coyle Financial Counsel LLC raised its holdings in shares of Abbott Laboratories by 14.0% in the 4th quarter. Coyle Financial Counsel LLC now owns 7,273 shares of the healthcare product maker’s stock valued at $911,000 after purchasing an additional 893 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group reduced their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday. Leerink Partners reduced their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. TD Cowen reduced their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Stifel Nicolaus cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $119.09.

Abbott Laboratories Stock Down 1.1%

Shares of Abbott Laboratories stock opened at $85.36 on Friday. The firm’s 50 day moving average price is $94.46 and its 200-day moving average price is $110.69. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The company has a market cap of $148.68 billion, a P/E ratio of 23.91, a PEG ratio of 1.44 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.